CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

Pulmonx Corporation | September 05, 2022 | Read time : 04:00 min

CONVERT Clinical

Pulmonx Corporation a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the collateral ventilation status in 78% of patients who were subsequently treated with Zephyr Valves.

The AeriSeal System is used to close collateral air channels in a target lung lobe of a patient with severe COPD/emphysema, making the patient eligible to then undergo Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Valves. Patients whose lungs have untreated collateral ventilation are currently ineligible for treatment with Zephyr Valves and have limited options once medical management alone does not control symptoms. Once the target lobe is converted from CV+ to CV-, patients can be treated with Zephyr Valves, which has been shown to improve lung function, quality of life, and exercise capacity for patients with severe COPD/emphysema.

The CONVERT study uses the AeriSeal System to close collateral air flow. Once the treated lobe tests negative for collateral ventilation Zephyr Valves are implanted to address hyperinflation of that target lobe to ease emphysema symptoms without major surgery. Successfully converted patients who received Zephyr Valves had clinically meaningful Target Lobe Volume Reduction with a mean reduction of greater than one (1) liter. The CONVERT trial is ongoing and full clinical outcomes of BLVR with Zephyr Valves were not reported at this time. However, results recently published from a single-center feasibility study at Macquarie University Hospital in Australia showed that the AeriSeal System successfully closed collateral air channels and allowed for successful clinical outcomes after treatment with Zephyr Valves.2 At 6 months, AeriSeal and Zephyr Valve treated CV+ patients experienced clinically meaningful improvements similar to improvements in CV- patients treated with Zephyr Valves alone.2 Improvements included


  • Lung function (FEV1 increase of 19.7%, Residual Volume decrease of 16.2%)
  • Quality of life (SGRQ score decrease of 15.1 points)
  • Exercise capacity (Six-Minute Walk Distance increase of 77.2 meters)


There were no serious adverse reactions experienced by patients in the Australian feasibility study; 20% of patients in the CONVERT Study experienced an inflammatory response following AeriSeal treatment - all were transient, medically managed, and resolved. The available data suggest that patients with collateral ventilation can undergo successful BLVR with Zephyr Valves following closure of the fissure gap with the AeriSeal System.

“This is very promising news for patients with advanced COPD. We know that treatment with Zephyr Valves can provide long-term improvements in lung function, breathing, and quality of life, but for patients with collateral ventilation, this minimally invasive treatment has not been available as an option,” explains Dr. Michela Bezzi, Department Head and Director Interventional Pulmonology - ASST Spedali Civili, University Hospital, Brescia, Italy. “Having a technology like the AeriSeal System to convert collateral ventilation positive patients to negative status means we can provide a treatment to patients who currently have very few options.”

This work reflects our continued commitment to developing and testing new medical technologies to help patients with severe lung disease breathe easier and have better quality of life. These early study results are encouraging and move us closer to the goal of helping severe emphysema patients who have collateral ventilation benefit from our proven Zephyr Valve treatment.”

Glen French, President and Chief Executive Officer of Pulmonx

About the CONVERT Study
CONVERT is a prospective, open-label, multi-center, single-arm study being conducted at up to 20 investigational sites. The study plans to enroll 140 subjects with severe emphysema and collateral ventilation in the target lobe. This protocol is designed to evaluate the utility of the AeriSeal System, which uses a synthetic polymer foam to occlude collateral air channels in a target lung lobe and convert the target lung lobe to having little to no collateral ventilation. Patients will then undergo Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves. Zephyr Valves are not effective if collateral ventilation (CV+) is present but once the target lobe is converted from CV+ to CV-, patients can be treated with Zephyr Valves which has been shown to improve lung function, quality of life, and exercise capacity for patients with severe COPD/emphysema.

About Zephyr Valves
The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema. Zephyr Valves are placed via bronchoscopy to block off a diseased portion of the lung to prevent air from getting trapped and reduce hyperinflation, which allows the healthier lung tissue to expand and take in more air. This results in patients being able to breathe easier, be less short of breath, and have an improvement in their quality of life.1 National and global treatment guidelines for COPD include Endobronchial Valves like Zephyr Valves with the Global Initiative for Chronic Obstructive Lung Disease giving valves an ‘Evidence A’ rating. More than 25,000 patients have been treated with the Zephyr Valve worldwide.

About Pulmonx Corporation
Pulmonx Corporation is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. 


G-20 First Health Working delegates visited KIMS Health to learn about its innovative healthcare practices and technology, including its commitment to Medical Value Travel and Wellness.


G-20 First Health Working delegates visited KIMS Health to learn about its innovative healthcare practices and technology, including its commitment to Medical Value Travel and Wellness.

Related News


Veradigm® and HeathVerity® Team up to Advance Cardiovascular and Diabetes Care

Veradigm® | February 14, 2023

On February 13, 2023, Veradigm®, a company specializing in healthcare technology and data solutions, and HealthVerity®, a pioneer in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, announced a collaboration progress real-world research and enhanced patient care for those with diabetes and cardiovascular disease. The cooperation enables full interoperability between Veradigm®'s Cardiovascular and Metabolic Registries data and de-identified patient information from HealthVerity® Marketplace, the nation's largest healthcare and consumer data ecosystem. This gives clinical researchers unprecedented access to regulatory-quality, HIPAA-compliant, and research-ready data to improve analytics and treatments. The HealthVerity® IPGE platform integrates technology and real-world data (RWD) to resolve disparate data to unique privacy-protected identities accurately, link them in a HIPAA-compliant manner, and exchange them for a variety of use cases. The largest U.S. outpatient cardiovascular quality improvement registry, the Veradigm® Cardiology Registry, has 102+ million records, 18.9+ million unique patient lives, 13,000 providers, and 4,000 office locations. The registry tracks data on cardiac conditions and records the patient's journey through key measures. In addition, the Veradigm® Metabolic Registry is the first clinical ambulatory registry that tracks and improves prediabetes, diabetes, and cardiometabolic care across primary and specialty care. The registry has 79+ million records representing 13.5+ million unique patient lives, 11,100 providers, and 3,400 office locations. Veradigm® and HealthVerity®'s collaboration uses the industry's most accurate patient matching and identity resolution technology, a vital component of the HealthVerity® IPGE Platform, to help researchers discover more comprehensive longitudinal patient journeys without patient fragmentation characteristic of conventional patient tokenization solutions. About Veradigm® Veradigm® is a healthcare technology company based in Chicago, Illinois. It creates value through a distinct combination of platforms, data, expertise, connectivity, and scale. The Veradigm® Network comprises a dynamic community of solutions and partners offering advanced insights, technology, and data-driven solutions, all of which interact to transform healthcare intelligently. In addition, it employs real-world insights to enhance real-world health and healthcare.

Read More


LMHS, InVita, Lifeline Launch iReferral to Boost Ohio Donation and Transplantation

Licking Memorial Health Systems (LMHS) | January 31, 2023

On January 30, 2023, Licking Memorial Health Systems (LMHS) integrated with Lifeline of Ohio and InVita Healthcare Technologies to launch iReferral to automate its identification and Lifeline's electronic referral of tissue, organ, and eye donors. iReferral will automatically recognize suitable donors and trace the referral process from a hospital to the organ procurement organization (OPO). Apart from gathering information on workflow, nursing time, and returns providers, it will increase opportunities for transplantation and donation, adhering to the federal government's rules. With over 100,000 patients on the nation's waiting list for a life-saving organ transplant, CMS laws require hospitals to direct all potential organ and tissue donors to their federally designated OPO. LMHS Vice President of Acute Care Services, Heather Burkhart, said, "Our staff is constantly looking for ways to enhance the high level of care provided to our patients. The automation offered through iReferral expedites the donor referral process allowing our healthcare providers to spend more time with the patient and their family during the most stressful of times while securing positive outcomes for transplant recipients." (Source – Cision PR Newswire) LMHS President and CEO Rob Montagnese said, "The new system furthers LMHS' efforts to integrate technology that directly impacts patient care while also providing the gift of life to the more than 3,100 people across the state that are waiting for organ, tissue, and eye donations". (Source – Cision PR Newswire) President and CEO of InVita Healthcare Technologies, Todd Collins, expressed, "Congratulations to LMHS and Lifeline of Ohio on their iReferral launch. This successful collaboration deploys scalable technology that helps shift nursing and provider resources back to patient care and provides greater access to life-saving gifts for the many in need by ensuring the critical first step of the intricate donation process is streamlined and made more reliable." (Source – Cision PR Newswire) About Licking Memorial Health Systems (LMHS) LMHS is a non-profit healthcare organization that consists of Licking Memorial Hospital, a physician corporation, and the Licking Memorial Health Foundation. Licking Memorial Health Foundation is funding and developing resources for LMHS. It utilizes the best technology to help patients and visitors with their safety and healthcare requirements. Founded in 1898, it has its headquarters in Newark (Ohio). Licking Memorial Development Council, a committee of business leaders in Licking County, supports LMH Foundation.

Read More


Advantus and GE HealthCare Announce Deal to Expand HTM Service Access

Advantus Health Partners | March 03, 2023

On March 2, 2023, Advantus Health Partners, a healthcare solutions company that improves supply chain models for healthcare organizations, and GE HealthCare, one of the world's largest medical equipment maintenance companies, announced a 10-year, $760 million agreement to provide GE HealthCare's HTM services to Advantus Health Partners' clients. Advantus Health Partners' clients can use the Healthcare Technology Management (HTM) program to manage all medical equipment in a healthcare facility. This includes regular maintenance, checking for recalls and taking care of them, cleaning and distributing the equipment, and so on. The program's proactive data security monitoring and efforts to standardize how healthcare organizations manage their equipment can help clients cut costs and boost productivity. Besides, the clients will also have access to Encompass, a real-time locating system from GE HealthCare that records and pinpoints a provider's equipment so that caregivers can spend more time with patients and less time looking for it. In addition, a proactive servicing plan for endoscopes is offered as part of an advanced scopes program and advanced asset management. Mohamed El-Demerdash, GE HealthCare U.S. and Canada Services President, expressed, "We are excited to build a healthier future by managing the comprehensive service needs of healthcare providers and helping ensure they have the latest technology available to provide quality care to their patients." He added, "Together with Advantus Health Partners, we will support health care organizations as they continue to evolve and adapt to meet their ever-changing needs and those of the communities they serve." (Source – Business Wire) Advantus Health Partners and GE HealthCare have expanded their partnership to provide healthcare providers with a scalable, end-to-end solution for controlling medical equipment performance and risk. About Advantus Health Partners Advantus Health Partners is a provider of healthcare solutions that aid in achieving corporate objectives through improved operations, corporate purchasing, and supply chain management. The company has expertise in distribution and logistics, inventory management, clinical integration, and many other adaptable supply chain solutions. It is passionate about reducing workflows and increasing scale. Its partners include ambulatory surgery centers, academic medical centers, critical access hospitals, regional integrated delivery networks, national health systems, and physician clinics.

Read More